This Article Free upon publication Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Related Articles

(Circulation. 2008;118:1307-1308.)
© 2008 American Heart Association, Inc.

Clinical Summaries

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Particulate Air Pollution as a Risk Factor for ST-Segment Depression in Patients With Coronary Artery Disease

 
Of the >1 million patients who suffer a myocardial infarction in the United States each year, one quarter to one third of survivors will die within 12 months, and a significant proportion will experience reinfarction or sudden death over the ensuing years. We evaluated the association of elevated air pollution with ST-segment depression in 48 patients followed up after hospitalization for myocardial infarction, acute coronary syndrome without infarction, or stable coronary artery disease without acute coronary syndrome. An interquartile increase in the previous 24-hour mean black carbon, a marker for traffic pollution, was associated with a 1.50-fold increased risk of ST-segment depression 0.1 mm (95% CI, 1.19 to 1.89) and a –0.031-mm (95% CI, –0.042 to –0.019) decrease in half-hour–averaged ST-segment level (continuous outcome). Effects were greatest within the first month after hospitalization and for patients with myocardial infarction during hospitalization or with diabetes. Our study suggests that the effects of air pollution on increased risk of ST-segment depression and ischemia or myocardial inflammation may be heightened in the immediate period after an acute coronary event. During this period, cardiac risk might be reduced by reduction in pollution exposure, including exposure to traffic. See p 1314.

	Differential Citation Rates of Major Cardiovascular Clinical Trials According to Source of Funding: A Survey From 2000 to 2005

 
Prior work indicates that therapeutic trials funded by for-profit organizations are more likely to report positive findings than trials funded by not-for-profit organizations. What impact, if any, funding source has on subsequent dissemination of trial data is uncertain. We assessed 303 consecutive superiority trials of cardiovascular medicine published between January 1, 2000, and . . . [Full Text of this Article]

Related Articles:

Calcification of the Thoracic Aorta as Detected by Spiral Computed Tomography Among Stable Angina Pectoris Patients: Association With Cardiovascular Events and Death

Alon Eisen, Alexander Tenenbaum, Nira Koren-Morag, David Tanne, Joseph Shemesh, Massimo Imazio, Enrique Z. Fisman, Michael Motro, Ehud Schwammenthal, and Yehuda Adler
Circulation 2008 118: 1328-1334. [Abstract] [Full Text]

Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial

Michael Werk, Soenke Langner, Bianka Reinkensmeier, Hans-Frank Boettcher, Gunnar Tepe, Ulrich Dietz, Norbert Hosten, Bernd Hamm, Ulrich Speck, and Jens Ricke
Circulation 2008 118: 1358-1365. [Abstract] [Full Text]

Recurrent Thrombosis and Survival After a First Venous Thrombosis of the Upper Extremity

L.E. Flinterman, A. van Hylckama Vlieg, F.R. Rosendaal, and C.J.M. Doggen
Circulation 2008 118: 1366-1372. [Abstract] [Full Text]

Particulate Air Pollution as a Risk Factor for ST-Segment Depression in Patients With Coronary Artery Disease

Kai Jen Chuang, Brent A. Coull, Antonella Zanobetti, Helen Suh, Joel Schwartz, Peter H. Stone, Augusto Litonjua, Frank E. Speizer, and Diane R. Gold
Circulation 2008 118: 1314-1320. [Abstract] [Full Text]

ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial

Christopher E. Buller, Yuling Fu, Kenneth W. Mahaffey, Thomas G. Todaro, Peter Adams, Cynthia M. Westerhout, Harvey D. White, Arnoud W.J. van 't Hof, Frans J. Van de Werf, Galen S. Wagner, Christopher B. Granger, and Paul W. Armstrong
Circulation 2008 118: 1335-1346. [Abstract] [Full Text]

Suppression of the JNK Pathway by Induction of a Metabolic Stress Response Prevents Vascular Injury and Dysfunction

Eberhard Schulz, Jörn Dopheide, Swenja Schuhmacher, Shane R. Thomas, Kai Chen, Andreas Daiber, Philip Wenzel, Thomas Münzel, and John F. Keaney, Jr
Circulation 2008 118: 1347-1357. [Abstract] [Full Text]

Impact of Inherited Thrombophilia on Venous Thromboembolism in Children: A Systematic Review and Meta-Analysis of Observational Studies

Guy Young, Manuela Albisetti, Mariana Bonduel, Leonardo Brandao, Anthony Chan, Frauke Friedrichs, Neil A. Goldenberg, Eric Grabowski, Christine Heller, Janna Journeycake, Gili Kenet, Anne Krümpel, Karin Kurnik, Aaron Lubetsky, Christoph Male, Marilyn Manco-Johnson, Prasad Mathew, Paul Monagle, Heleen van Ommen, Paolo Simioni, Pavel Svirin, Daniela Tormene, and Ulrike Nowak-Göttl
Circulation 2008 118: 1373-1382. [Abstract] [Full Text]

Differential Citation Rates of Major Cardiovascular Clinical Trials According to Source of Funding: A Survey From 2000 to 2005

David Conen, Jose Torres, and Paul M Ridker
Circulation 2008 118: 1321-1327. [Abstract] [Full Text]